D.E. Shaw & Co
AGRX

D.E. Shaw & Co’s Agile Therapeutics AGRX Stock Holding History

D.E. Shaw & Co’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,099
Closed -$460K – 6013
2022
Q1 		$460K Buy
1,099
+18
+2% +$11.5K ﹤0.01% 4420
2021
Q4 		$1.05M Buy
1,081
+920
+571% +$1.3M ﹤0.01% 3890
2021
Q3 		$310K Buy
161
+114
+243% +$258K ﹤0.01% 4335
2021
Q2 		$126K Sell
47
-4
-8% -$13.2K ﹤0.01% 4522
2021
Q1 		$212K Sell
51
-8
-14% -$43.2K ﹤0.01% 3836
2020
Q4 		$336K Buy
59
+32
+119% +$188K ﹤0.01% 3563
2020
Q3 		$162K Buy
+27
New +$155K ﹤0.01% 3636

Other funds holding AGRX

PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $93.1B AUM 61.18% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Citigroup
Citigroup New York $157B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $77.3B AUM 36.07% 1-Year Est. Return